Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 12/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.54 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.54 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495904 | 0.95 | GRIN2B (0.67) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 | |
| SCHEMBL30228590 | 0.93 | GRIN2B (0.58) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 | |
| SCHEMBL30492326 | 0.93 | GRIN2B (0.58) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 | |
| SCHEMBL30492373 | 0.93 | GRIN2B (0.58) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 | |
| SCHEMBL296939 | 0.86 | SMN1; SMN2 (0.65) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 | |
| SCHEMBL31210641 | 0.86 | SMN1; SMN2 (0.54) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 | |
| SCHEMBL19024446 | 0.85 | SMN1; SMN2 (0.54) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 | |
| SCHEMBL31714072 | 0.85 | GRIN2B (0.56) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 | |
| Hydrochloric Acid SCHEMBL19024588 | 0.85 | SMN1; SMN2 (0.53) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 | |
| SCHEMBL1972315 | 0.85 | SMN1; SMN2 (0.64) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20080200460-A1 | Chemical Compounds | BROWN DEARG | 2008-08-21 | — | — | US | disclosed |
| US-20080200460-A1 | Chemical Compounds | BROWN DEARG | 2008-08-21 | — | — | US | disclosed |
| US-20080200460-A1 | Chemical Compounds | BROWN DEARG | 2008-08-21 | — | — | US | disclosed |
| EP-1833792-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS CCR5 MODULATORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006067385-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200460-A1 | Chemical Compounds | CCR5, CXCR4, CXCR5 | GRIN2B 759/4885SMN1; SMN2 3791/4885NPC1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.